Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices
Open Access
- 10 April 2015
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 123 (5) , 282-288
Abstract
BACKGROUND: In the United States, human papillomavirus (HPV) and Papanicolaou (Pap) testing (cotesting) for cervical screening in women ages 30 to 65 years is the preferred strategy, and cytology alone is acceptable. Recently, a proprietary automated test for identifying high‐risk HPV types for primary cervical screening was approved by the US Food and Drug Administration. The objective of the current study was to document extensive cervical screening among these screening options.METHODS: To investigate the sensitivity of various testing options for biopsy‐proven cervical intraepithelial neoplasia grade 3 or worse (≥CIN3) and cancer, the authors reviewed 256,648 deidentified results from women ages 30 to 65 years at the time of cotest who had a cervical biopsy specimen obtained within 1 year of the cotest.RESULTS: A positive cotest result was more sensitive (98.8%; 4040 of 4090 cotests) for diagnosing ≥CIN3 than either a positive HPV‐only test (94%; 3845 of 4090 HPV‐only tests) or a positive Pap‐only test (91.3%; 3734 of 4090 Pap‐only tests; P < .0001). A positive Pap‐only result was more specific (26.3%; 66,145 of 251,715 Pap‐only tests) for diagnosing ≥CIN3 than a positive HPV‐only test (25.6%; 64,625 of 252,556 HPV‐only tests) or a positive cotest (10.9%; 27,578 of 252,558 cotests; P < .0001). Of 526 cervical cancers, 98 (18.6%) were HPV‐only negative, 64 (12.2%) were Pap‐only negative, and 29 (5.5%) were cotest negative.CONCLUSIONS: Compared with HPV‐only testing, cotesting was more sensitive for the detection of ≥CIN3 in women ages 30 to 65 years. The current data suggest that approximately 19% of women with cervical cancer may be misdiagnosed by an HPV‐only cervical screen. It is important to consider these data as the guidelines for cervical cancer screening undergo revision. Cancer (Cancer Cytopathol) 2015;123:282–8. © 2015 The Authors. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.Keywords
This publication has 29 references indexed in Scilit:
- Co-testing for detection of high-grade cervical intraepithelial neoplasia and cancer compared with cytology alone: a meta-analysis of randomized controlled trialsJournal of Public Health, 2013
- Confirming Suboptimal Adherence to HPV Cotesting Guidelines in an Academic Center in VermontAmerican Journal of Clinical Pathology, 2013
- Practice Patterns in Cervical Cancer Screening and Human Papillomavirus TestingAmerican Journal of Clinical Pathology, 2012
- Screening Test Results Associated With Cancer Diagnoses in 287 Women With Cervical Squamous Cell CarcinomaArchives of Pathology & Laboratory Medicine, 2012
- Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA studyThe Lancet Oncology, 2011
- Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practiceThe Lancet Oncology, 2011
- Comparison of the Hybrid Capture II Assay With the Human Papillomavirus DNA Chip Test for the Detection of High-Grade Cervical LesionsInternational Journal of Gynecological Cancer, 2009
- Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer ScreeningJNCI: Journal of the National Cancer Institute, 2009
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006
- Investigation of human papillomavirus by hybrid capture II in cervical carcinomas including 113 adenocarcinomas and related lesionsInternational Journal of Gynecological Cancer, 2006